Seeking Alpha

Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum

Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, ...
Nasdaq

Kymera Therapeutics Presents Promising Preclinical Data for KT-621, a First-in-Class Oral STAT6 Degrader, Demonstrating Comparable Efficacy to Dupilumab in Chronic Asthma Model

KT-621 demonstrated comparable or superior activity to dupilumab in reversing disease progression in a chronic asthma model, indicating its potential as an effective treatment option. Kymera ...
Seeking Alpha

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Nasdaq

Kymera Therapeutics Reports Positive Phase 1 Results for KT-621, a Once-Daily Oral STAT6 Degrader, Surpassing Targets and Demonstrating Strong Safety Profile

Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. KT-621 demonstrated superior Th2 biomarker reductions compared to ...
Houston Chronicle

Harris County's new 621 area code scheduled to arrive in January 2025

A really big change is coming in January 2025. No, not that one. Harris County is getting a new area code, which has been reported. But now, according to a press release from internet and phone ...